News
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the
NanoString Launches Integrated Informatics to Facilitate Spatial Biology Research Using Next Generation Sequencing
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced a seamless, cloud-based workflow that improves the
DGAP-News: M1 Kliniken AG announces financials for Q1-2022: further growth of Beauty segment; ongoing optimisation of Trade segment
Nicox (COX): Eye health portfolio targets large markets
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today presented
Straumann Group to acquire PlusDental, a doctor-led clear-aligner treatment solutions provider in Europe
QIAGENs umweltfreundlichere Produkte erhalten das renommierte ACT-Label
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass seine kürzlich eingeführten umweltfreundlicheren QIAwave-Kits zur Extraktion von Nukleinsäuren mit dem angesehenen
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its recently launched, environmentally friendlier QIAwave nucleic-acid extraction kits have received the prestigious ACT
GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal
DGAP-News: Formycon appoints Dr. Stefan Glombitza as CEO and sets the course for the future by appointing the two experienced pharmaceutical managers Nicola Mikulcik and Dr. Andreas Seidl to the Executive Board
DGAP-Adhoc: Formycon announces changes to its Executive Board
Evolva business update: On track to reach 2022 guidance
CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
Regulatory News:
This replaces the announcement made at 4:40PM EDT/20:40 CEST on May 18 due to the following correction: Updated date in "First Quarter Operational Highlights" section.
NANOBIOTIX Provides First Quarter Operational and Financial Update
Regulatory News:
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for
Agilent Announces Cash Dividend of 21 Cents per Share
Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 21 cents per share of common stock will be paid on July 27, 2022, to all shareholders of record as of the close of
DGAP-News: ABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents
AMN Highest Ranked Healthcare MSP in 2022 Global Customer Satisfaction Awards
AMN Healthcare (NYSE: AMN), the nation’s leader in healthcare total talent solutions, achieved the highest ranking for a healthcare Managed Services Program in the HRO Today 2022 Baker’s Dozen
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, provided updated clinical data from the ongoing AAVance
DGAP-News: Formycon Publishes Annual Financial Statements for the 2021 Financial Year
Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Savara to Present at H.C. Wainwright Global Investment Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright Global
Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2022
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including